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Abstract
DEAD box protein, DDX3, is aberrantly expressed in breast cancer cells ranging from weakly invasive to aggressive
phenotypes and functions as an important regulator of cancer cell growth and survival. Here, we demonstrate that hypoxia
inducible factor-1a is a transcriptional activator of DDX3 in breast cancer cells. Within the promoter region of the human
DDX3 gene, we identified three putative hypoxia inducible factor-1 responsive elements. By luciferase reporter assays in
combination with mutated hypoxia inducible factor-1 responsive elements, we determined that the hypoxia inducible
factor-1 responsive element at position -153 relative to the translation start site is essential for transcriptional activation of
DDX3 under hypoxic conditions. We also demonstrated that hypoxia inducible factor-1 binds to the DDX3 promoter and
that the binding is specific, as revealed by siRNA against hypoxia inducible factor-1 and chromatin immunoprecipitation
assays. Thus, the activation of DDX3 expression during hypoxia is due to the direct binding of hypoxia inducible factor-1 to
hypoxia responsive elements in the DDX3 promoter. In addition, we observed a significant overlap in the protein expression
pattern of hypoxia inducible factor-1a and DDX3 in MDA-MB-231 xenograft tumors. Taken together, our results
demonstrate, for the first time, the role of DDX3 as a hypoxia-inducible gene that exhibits enhanced expression through the
interaction of hypoxia inducible factor-1 with hypoxia inducible factor-1 responsive elements in its promoter region.
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Introduction
Human DDX3 is a member of the DEAD-box family of RNA
helicases and is located on the X chromosome [1]. DEAD-box
RNA helicases have been shown to function in RNA metabolism
including translation, ribosome biogenesis, pre-mRNA splicing,
and nucleo-cytoplasmic RNA transport [2–4]. Human DDX3
shares significant amino-acid sequence homology with orthologs
from several species including yeast (Ded1), Drosophila (Bel),
Xenopus (An3), and murine (PL10) [5–8]. Thus, natural selection
of an ancestral DDX3 protein with characteristics that have been
passed along to higher organisms is an indication that this protein
is involved in cellular pathways that are essential to survival. In
humans DDX3 has a function in folliculogenesis as its deletion or
dysfunction represents an important genetic cause of primary
amenorrhea or impairment of female fertility [9]. Recently DDX3
has been the focus of a great deal of research because of its
involvement in the replication of the human immunodeficiency
virus, hepatitis C virus, and poxviruses [10–16].
Recent work indicates that DDX3 can participate in the
transcriptional regulation of a diverse set of genes involved in
apoptosis and cellular transformation in ways that impact cancer
progression [17]. It has been demonstrated that apoptosis was
triggered by DDX3 modulated transactivation of the expression
of p21
waf1/cip1 gene [18]. The modulation of p21
waf1/cip1 gene
expression accounts for the growth-suppressive effect of DDX3 in
hepatocellular cell lines. On the other hand, our work has shown
that over-expression of DDX3 brought about a cellular
transformation leading to the down-regulation of E-cadherin
expression in immortalized breast epithelial cells (MCF 10A cells)
[19]. Down-regulation of E-cadherin is a marker of an epithelial
mesenchymal transition (EMT) phenotype, which is associated
with cancer progression in several cancers [19–22]. We also
found that DDX3 expression is directly correlated with
tumorigenesis in a panel of breast epithelial cell lines ranging
from non-tumorigenic (low DDX3) to highly aggressive cancer
phenotypes (high DDX3) [19]. In MDA-MB-231, a highly
aggressive metastatic breast cancer cell line, DDX3 was found
within an anti-apoptotic complex consisting of glycogen synthase
kinase 3 (GSK3) and cellular inhibitor of apoptosis 1 (c-IAP1),
which is an indication of its importance in the therapeutic
resistance of tumor cells to TRAIL receptor antibody therapy
[23]. Thus, DDX3 has diverse functions in a variety of cell types,
in breast cancer cells DDX3 augments cell proliferation whereas
in hepatocellular carcinoma cells it promotes growth arrest and
tumor suppressing activities.
Hypoxia is a major characteristic of solid tumors and a
condition that affects genome-wide changes in gene expression,
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particularly respiration and metabolism [23–29]. Expression of
hypoxia-responsive genes is predominately regulated by hypoxia
inducible factors (HIFs) [23,25–34]. HIFs are basic helix-loop-
helix/PAS transcription factors consisting of an alpha subunit (e.g.,
HIF-1a) and a b subunit, i.e., aryl hydrocarbon receptor nuclear
transporter (ARNT) [30]. HIF-1 is expressed in most tissues and
functions as the principal transcriptional regulator of most HIF
responsive element (HRE) containing genes while HIF-2 exhibits
restricted expression and a more limited scope of regulation [35].
Under normoxic conditions, HIF-1a and 2a are subjected to
ubiquitination and proteasomal degradation [36]. However, under
hypoxic conditions, HIF-1a or 2a heterodimerize with ARNT
forming HIF-1 and HIF-2, which bind to hypoxic response
elements (HREs) within the promoters of target genes to promote
transcription [37,38]. HREs have been found in a remarkably
large set of genes that affect many different genetic programs,
including proliferation, differentiation, tissue-specific responses,
and cell death [39]. During our studies of DDX3 we discovered
putative HRE sequences within its promoter. Therefore, we
hypothesized that the hypoxic microenvironment within solid
tumors activates the expression of DDX3.
In this study, we investigated whether expression of DDX3 gene
is up-regulated by HIF-1a or HIF-2a in response to hypoxia in
human breast epithelial cell lines. Our data provide evidence that
hypoxic induction of the DDX3 gene is mediated by transactiva-
tion of DDX3 promoter by HIF-1a through a consensus HRE
binding site.
Results
Hypoxia regulates DDX3 expression in breast cancer cells
To investigate whether the expression of DDX3 is regulated by
hypoxia, we compared the mRNA levels of DDX3 in cells
cultured under normoxic (20% O2) and hypoxic (1% O2)o r
hypoxia-mimetic (cobalt chloride: CoCl2) conditions. A time
course (8, 12, and 24 h time points) experiment in MCF 10A
cells demonstrated that the induction of DDX3 mRNA was
transient (Figure 1a). DDX3 mRNA expression levels increased
to 2.3 and 1.4 fold in MCF 10A cells at 8 h following exposure to
CoCl2 or 1% O2 respectively but after 12 h in 1% O2 and at
2 4hi nC o C l 2 DDX3 mRNA levels returned to or fell below
normoxic levels (Figure 1a). To confirm the generality of this
effect, we exposed weakly tumorigenic MCF 7 cells, to CoCl2 or
1% O2 and measured DDX3 mRNA levels. In the case of 1%
O2 treatment, DDX3 mRNA levels were up-regulated approx-
imately two fold relative to that of normoxic levels, at all time
points tested (Figure 1b). In contrast, following CoCl2 exposure,
levels of DDX3 mRNA reached a similar 2.0 fold increase at 8 h
and then decreased to approximately normoxic levels at 12 and
24 h (Figure 1b). We next proceeded to test this result at the
protein level. MCF 10A and MCF 7 cells were treated with
either CoCl2 or 1% O2 or left under normoxia and total protein
extracts were prepared and analyzed for DDX3 and HIF-1a
protein levels by immunoblot. The time course examined was
identical as that used during the mRNA experiments. In MCF
10A cells, relative to normoxic conditions, DDX3 protein levels
Figure 1. Effect of hypoxic conditions on the expression of the DDX3 gene in breast epithelial cells. MCF 10A (a & c) and MCF 7 (b & d)
cells were cultured under normoxic conditions (20% O2) or subjected to 200 mM CoCl2 or 1% O2 for 8, 12 and 24 h (a & b) qRT-PCR analysis was
performed using specific primers for human DDX3 and HPRT as an internal normalization control. The expression level under normoxia was set to 1.
DDX3 protein levels (c & d) in cell lysates of MCF 10A and MCF 7 cells were determined by immunoblots using anti-DDX3 antibodies. In these cases,
HIF-1a and GAPDH served as controls indicating hypoxic conditions and equal protein loading respectively. Error bars represent 6SD.
doi:10.1371/journal.pone.0017563.g001
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throughout the duration of the experiment. However, with 1%
O2 exposure DDX3 protein levels in MCF 10A cells increased at
8 h and then began to decrease by 12 h reaching approximately
normoxic conditions by 24 h (Figure 1c). Relative to normoxic
levels, DDX3 protein levels in MCF 7 cells increased by 8 h of
CoCl2 or 1% O2 treatment, stayed elevated at 12 h during 1%
O2 treatment but started to decline at this time point during
CoCl2 treatment, and then declined back to normoxic levels by
24 h of CoCl2 treatment and to levels approaching normoxic
levels during 1% O2 treatment (Figure 1d). HIF-1a proteins
levels were used as a positive control indicative of hypoxic
conditions. Overall, these data demonstrate that hypoxia induces
DDX3 expression of both mRNA and protein levels in normal
and malignant breast cells.
DDX3 gene expression is dependent on HIF-1a
stabilization during CoCl2 treatment
To determine the role of HIF-1 or HIF-2 in regulating the
expression of DDX3, HIF-1a expression was knocked down in
MCF 10A and MCF 7 cells with shRNAs targeting HIF-1a,
which generated MCF 10A-shHIF-1a and MCF 7-shHIF-1a
cells. These stable cell lines were subjected to CoCl2 treatment
and the mRNA levels of DDX3, HIF-1a,a n d- 2 a were
determined 8 and 12 h later. As shown in Figure 2a and b,
the presence of CoCl2 did not induce HIF-1a mRNA in MCF
10A-shHIF-1a or MCF 7-shHIF-1a cells, as compared to control
cells. In contrast, 8 h of CoCl2 treatment caused an increase in
HIF-2a mRNA in MCF 10A-shHIF-1a cells and an increase in
HIF-2a a t1 2hi nM C F7 - s h H I F - 1 a cells, indicating that the
shRNA effect was specific to HIF-1a. Consistent with the
repression of HIF-1a expression, DDX3 mRNA was not
increased in either shHIF-1a expressing cell line under CoCl2
conditions. However, the level of DDX3 mRNA is slightly
decreased at 12 h in MCF 10A and MCF 7 cell lines. We next
performed immunoblot analysis on identical samples to deter-
mine whether the difference in the expression of HIF-1a, HIF-
2a and DDX3 mRNA in these cell lines influences their protein
expression. Figure 2c and d demonstrates that DDX3 protein
levels mirrored the mRNA levels seen during hypoxic simulation
in HIF-1a knockdown MCF 10A and MCF 7 cell lines while
HIF-2a levels were up-regulated. These data provide the first
direct demonstration of a specific regulation of an important
RNA helicase gene by HIF-1.
Figure 2. Specificity of HIF-1a dependent activation of the DDX3 gene. Stable MCF 10A and MCF 7-HIF-1a shRNA clones were generated. (a)
MCF 10A-shHIF-1a and (b) MCF 7-shHIF-1a cells were subjected to 200 mM CoCl2 for the indicated times. qRT-PCR analysis was performed using
specific primers for human DDX3, HIF-1a and HIF-2a. DDX3, HIF-1a, and HIF-2a protein levels in cell lysates of MCF 10A-shHIF-1a (c) and MCF 7-shHIF-
1a (d) cells were examined by immunoblots using protein specific antibodies. GAPDH served as a loading control. Error bars represent 6SD.
doi:10.1371/journal.pone.0017563.g002
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line
We next investigated whether regulation of DDX3 by hypoxia
occurs at the transcriptional level. To identify putative transcrip-
tion factors involved in the regulation of DDX3 gene expression,
we retrieved the DDX3 promoter sequence (Acc. No NG_012830)
and analyzed it at the Genomatix site (http://www.genomatix.
com). At least three putative core HRE (A/GCGTG) sites were
found within the 2.1 kb DDX3 promoter region at 2153 (HRE-
1), 2699 (HRE-2) and 21021 (HRE-3), relative to the ATG
translation start codon (Figure 3a). To assess the functional activity
of DDX3 promoter, transfection experiments were performed in
MCF 7 breast cancer cells, using different DDX3 promoter-
reporter vector constructs. Figure 3b, left panel, depicts a
schematic representation of the different promoter-reporter
deletion constructs (D1 – D6) used. Our results indicate that
there may be a repressor(s) within the 21478 to 22000 bp range
(compare D1 expression to that of D2; Figure 3b). In addition, our
D3 construct indicates that an enhancer(s) apparently is present
within the 2581 to 21478 region as reporter activity relative to
that of the D2 construct dropped with the removal of this region.
We also observed a large decrease in promoter activity with the
deletion of proximal promoter regions as seen with a comparison
of the reporter activity of constructs D4, D5 and D6 to that of D2
(Figure 3b). Thus, under the conditions used in MCF 7 cells, the
1.48 Kb promoter region was the most active of the reporter
constructs. To test whether exogenous HIF-1a over expression can
cause a stimulatory effect on DDX3 promoter activity in normoxic
conditions, we co-transfected the DDX3 promoter-reporter vector
constructs with a vector that provides for constitutive expression of
HIF-1a. As shown in Figure 3c, under these conditions the pattern
of reporter activities mirrored that seen in Figure 3B but the
activities were increased by an order of magnitude. This data
provides further direct evidence that HIF-1a is involved with the
regulation of DDX3 expression.
Identification of functional HREs in the DDX3 promoter
Site directed mutagenesis was performed within individual
HREs (HRE-1: M1 or HRE-2: M2 or HRE-3: M3) as well as in
combinations of HREs (M1+M2 or M1+M3 or M2+M3 or
Figure 3. Characterization of the putative HRE containing sequences of the human DDX3 promoter. (a) Schematic representation of
putative core HRE sequences in the promoter region of the DDX3 gene. (b) Linear representations of the DDX3 promoter-reporter constructs and the
relative firefly luciferase activity of each in transient transfection assays in MCF 7 cells with pRRL-CMV (renilla luciferase expressing vector) asa n
internal control. After transfection cells were incubated in normoxia for 24 h Relative firefly luciferase activities are presented as a histogram at the
right. (c) Effects of over-expression of HIF-1a in MCF 7 cells under normoxia. Cells were co-transfected with the DDX3 promoter-reporter constructs
shown in (b), with pCDNA-HIF-1a (constitutive HIF-1a expressing vector), and pRRL-CMV as the internal control. Relative firefly luciferase activities are
presented. Mean values from three independent transfections are shown. Error bars represent 6SD.
doi:10.1371/journal.pone.0017563.g003
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depicted in Figure 4a. To determine if HIF-1 binds to any or all of
these putative HRE sequences, mutated promoter-reporter
constructs were transiently transfected into MCF 7 cells and the
cells were incubated for 24 h under normoxic conditions and then
harvested for luciferase assay. Again, the activity of the D2
construct was relatively high in MCF 7 cells (Figure 4b). However,
relative to the D2 construct, we found a 35% reduction in the
mutated HRE-1 (M1) promoter activity (Figure 4b). In contrast,
disruption of HRE-2 (M2) or HRE-3 (M3) enhanced luciferase
activity under normoxic conditions. We further demonstrated that
combinations of double or triple mutation constructs that included
mutated HRE-1 (M1), i.e., M1+M2 or M1+M3 or M1+M2+M3,
reduced reporter activity to levels similar to or lower than that of
M1 activity (Figure 4b). In addition, exclusion of M1 as a double
mutation, i.e., M2+M3, did not inhibit reporter activity (Figure 4b).
To determine whether the basal reporter expression from DDX3
promoter-report constructs in normoxia is due to constitutive
expression/stabilization of HIF-1a, we transiently transfected D2
and the mutated promoter-reporter constructs into MCF-7-
shHIF-1a cells. As shown in Figure 4c, under shHIF-1a conditions
the reporter activities shown in Figure 4b were decreased in all
cases while the pattern of activities was identical to that observed
in Figure 4a. To study the activities of the mutated promoters
under HIF-1a stabilized conditions, the reporter constructs were
transfected into MCF 7 cells that were then treated with CoCl2.A s
shown in Figure 4d reporter activities were enhanced following
CoCl2 treatment without changing the pattern seen in Figure 4a.
To further explore HIF-1 regulation of DDX3 expression we co-
transiently transfected MCF 7 cells with the mutated promoter-
reporter constructs and a constitutive expressing HIF-1a vector
construct (Figure 4e). Under these conditions all reporter activities
roughly tripled and the loss of the HRE-1 site showed qualitatively
the same diminishing effect on reporter activities. In total, the
overall patterns of activities seen in Figure 4 remained qualitatively
very similar regardless of the conditions tested and all these results
indicate that loss of HRE-1 alone was sufficient to decrease
reporter activity to roughly the same degree as what occurred
Figure 4. Identification of functional HRE in the DDX3 promoter. (a) The regions of the individually mutated HREs-1-3 (Mut1-3) are indicated
schematically. MCF 7 and MCF 7-shHIF-1a cells were transfected with wild-type (D2), singly (M1, M2, M3), doubly (M1+M2, M1+M3, M2+M3) or triply
(M1+M2+M3) mutated promoter-reporter constructs, as indicated. (b & c) After transfection MCF 7 or MCF 7-shHIF-1a cells were cultured under
normoxia. (d) After transfection MCF 7 were cultured in presence of CoCl2. (e) Each transfection of MCF 7 cells included co-transfection with a
constitutive HIF-1a expression vector. Histograms show relative firefly luciferase activity. Each experiment was performed in triplicate on at least three
separate occasions. Error bars represent 6SD.
doi:10.1371/journal.pone.0017563.g004
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other hand, loss of either HRE-2 or HRE-3 or both HRE-2 + 3
either caused an increase in reporter activities or had no impact on
reporter activity respectively.
Chromatin immunoprecipitation assay for HIF-1a binding
to the DDX3 promoter
To further demonstrate that HIF-1 physically binds to the
DDX3 promoter and regulates DDX3 gene activity, MCF 10A
cells were exposed to hypoxia for 8 h and the binding of HIF-1
to DDX3 promoter was analyzed using a ChIP assay. PCR was
designed to amplify the region from 2423 to 2115 bp of the
DDX3 promoter, as schematically shown in Figure 5 DNA/
protein complexes precipitated with an anti-HIF-1a antibody
resulted in a detectable PCR-amplified DDX3 promoter-specific
product only in the case of cells treated with hypoxia (Figure 5:
lane 4). The positive controls: unprocessed total chromatin as
well as anti-acetyl-histone precipitations (Figure 5: lane 2 and 3
respectively), also gave amplified products. However, no specific
DDX3 amplified products were observed in preparations of
DNA that were obtained from cells left in normoxia and the use
of a nonspecific antibody during the precipitation step also gave
a negative result (Figure 5: lane 5 and 6 respectively). Together,
these results indicate that HIF-1 binds directly to the
endogenous DDX3 promoter in live cells under hypoxic
conditions. Overall this experiment provides strong support of
the promoter-reporter activity assays and indicates that at least
one functional HRE sequence can be assigned to this region of
the DDX3 promoter.
Gross co-localization of DDX3 and HIF-1a protein
expression in xenograft tumor samples
DDX3 and HIF-1a are highly expressed in the very aggressive
breast cancer cell line, MDA-MB-231. To understand the
possible HIF-1 mediated regulation of DDX3 in aggressive
cancers, we knocked down HIF-1a levels in MDA-MB-231 using
the lentiviral based shRNA described above. As shown in
Figure 6a, HIF-1a was undetectable in MDA-MB-231-shHIF-
1a under normoxia as well as during CoCl2 treatment, while
being readily detectable in MDA-MB-231-shLuc cell lysates. To
correlate the expression levels of DDX3 to that of HIF-1a levels,
qRT-PCR and immunoblot scoring for DDX3 transcript and
protein were performed on identical samples. Figure 6b shows
that levels of DDX3 transcript and protein were reduced in
MDA-MD-231-shHIF-1a cells. These results support the report-
er assays and indicate that HIF-1 is a direct or indirect
transcriptional regulator of DDX3 in aggressive breast cancer
cells. We next examined if there is a correlation between DDX3
and HIF-1a protein expression in a mouse MDA-MB-231
xenograft model using anti-DDX3 and anti-HIF-1a antibodies
to score for these proteins in immunohistochemical assays.
Figure 6c shows a representative immunohistochemical staining
of DDX3 and HIF-1a in sequential MDA-MB-231 tumor slices
and the overlapping pattern of expression of these proteins within
a growing tumor. Thus, much of the brown nuclear staining
pattern of HIF-1a (right tumor slice), which is visible throughout
much of the central and into the lower right regions of the slice,
co-registers with the brown cytoplasmic staining pattern of
DDX3 (left tumor slice) in an adjacent tumor slice and that the
same areas of the slices (e.g., upper left regions) show no staining.
This provides good evidence that HIF-1 may be contributing to
the up-regulation of DDX3 expression in hypoxic regions of
breast tumors.
Discussion
Hypoxia is one of the major stress inducing factors that arises
within solid tumors including breast tumors [40,41]. A low oxygen
condition stabilizes HIF-1a and HIF-2a and these can then
dimerize with ARNT (HIF-1b) forming HIF-1 and HIF-2, which
subsequently modulate gene expression programs that effectively
promote cell survival [42,43]. The importance of chronic hypoxia
on cancer cells is that this condition has been associated with the
generation of aggressive phenotypes, chemo- and radiation
resistance, and metastatic potential [44–46]. Our recent studies
have provided evidence that in breast cancer up-regulation of
DDX3 expression can be associated with an aggressive phenotype
and down-regulation or targeted inhibition of DDX3 can mitigate
its actions [19]. Whether DDX3 is a contributing factor to the
aggressive phenotype of hypoxic cancer cells is not known and the
question of transcriptional regulation of human DDX3 during
hypoxia has not previously been addressed. Given this, it was
pertinent to ask about the molecular mechanisms that might
induce DDX3 expression in response to hypoxia. In the present
study, we provide the first evidence that hypoxia induces the
expression of DDX3 in human breast epithelial cells and moreover
that this regulation is mediated in part by HIF-1 binding to
HRE(s) within the DDX3 promoter.
The in vitro increase in the expression of DDX3 mRNA
measured in both MCF 10A and MCF 7 cell lines following
hypoxic treatment occurred in a time dependent manner and was
transient. This is consistent with other reports that have shown
that measured increases in mRNA expression during hypoxia can
be dependent on the severity as well as duration of the treatment
and the stability of an mRNA in a given cell line [45,47]. For
example, Guo et al. reported that the induction of the CYGB gene
in response to hypoxia was instantaneous but the time that the
maximum mRNA level was reached varied with the cell line and
thus was found at 3 h in BEAS-2B cells and 6 h in HeLa cells [48].
Maximum mRNA expression of DDX3 is observed in both cell
lines tested here at 8 h of hypoxic treatment but in MCF 10A cells
these levels declined at later time points, which was also the case
during CoCl2 treatment of MCF 7 cells. Our immunoblot data
mirrors the mRNA data in that DDX3 protein levels increased in
Figure 5. ChIP assay: in vivo binding of HIF-1 to the DDX3
promoter in MCF 10A cells. At the top of the gel is a schematic
representation of the DDX3 promoter. Arrows flank the region (-423 to
-115) amplified by PCR with DDX3 promoter specific primers. Gel shows:
lane 1- molecular weight (MW) marker, lane 2- total input chromatin,
lane 3-acetyl histone H3 precipitation, lane 4-anti-HIF-1a precipitation
under hypoxic conditions, lane 5-anti-HIF-1a under normoxic condi-
tions, and lane 6-anti-actin precipitation. Identical volumes from each
final precipitation were used for PCR (except for the input chromatin,
which was diluted 100x).
doi:10.1371/journal.pone.0017563.g005
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but reflect that the protein stability was higher than the mRNA
stability in MCF 10A cells. Recent evidence has shown that HIF-1
and not HIF-2 is the principal HIF involved with the regulation of
the genes in response to hypoxia in cancer cell lines including
hepatoma, neuroblastoma, and breast cancer [49,50]. Thus, we
used shRNA knockdown of HIF-1a to determine the specificity of
hypoxia induced DDX3 expression. The data obtained with the
HIF-1a knockdown in MCF 10A and MCF 7 cell lines provide
consistent evidence supporting the major involvement of HIF-1
and not HIF-2 in the transcriptional activation of DDX3 by
hypoxia and indicated that DDX3 could be considered a new
member of the growing family of HIF-1 targeted genes.
In order to define the binding sites of HIF-1 in the DDX3
promoter that are contributing to increased expression under
hypoxic conditions, we performed luciferase based reporter assays
using 2 kb gene sequence that is immediately up stream of the
translation start site [51]. In our luciferase reporter studies with
MCF 7 cells we observed that the promoter fragment that
extended approximately 1.5 kb upstream from the translation start
site showed basal activity that was relatively high in comparison to
the other promoter-reporter constructs tested. This is consistent
with a similar high basal reporter activity reported during a
characterization of the DDX3 promoter in two human embryonic
carcinoma cell lines NEC8 and NEC14 [51]. This is likely due to
the binding of basal levels of transcriptional activators to the
upstream region of DDX3 promoter. When we co-transfected a
constitutively expressing HIF-1a vector along with the promoter-
reporter constructs the reporter activity increased by an order of
magnitude for all the promoter constructs expect the two that lack
the 2320 bp region, i.e., the region closest to the translation start
site. This indicates that HIF-1 directly or indirectly can regulate
DDX3 expression via a cis-element(s) located within the 2320 bp
proximal promoter region that is particularly critical to the
modulation of expression by HIF-1. An analysis of the 1.5 kb
DDX3 promoter sequence showed that it contains at least 3 core
hypoxia response elements (HREs), A/GCGTG, i.e., HIF-1
binding sites. Of the various mutated promoter-reporter constructs
tested the mutation of the site we designated as HRE-1, located
within the 2320 bp region, appeared to have the largest impact
on a decrease of reporter activity, under both normoxic and
hypoxic mimic conditions. Recently, constitutive expression of
HIF-1a was detected in MCF 7 cells under normoxia [52], which
we also observed (see Figure 1d: lane 1). To understand if the high
basal reporter activity is due to constitutive stabilization of HIF-1a
in MCF 7 cells we estimated the reporter activity in MCF
Figure 6. Correlation between HIF-1a and DDX3 protein expression in MDA-MB-231 breast cancer cells. (a) Immunoblot showing
expression levels of HIF-1a following CoCl2 treatment in HIF-1a knockdown cells. (b) Histogram showing relative fold expression of DDX3 mRNA
protein levels of MDA-MB-231 versus MDA-MB-231-shHIF-1a cells. Expression of DDX3 was downregulated in MDA-MB-231-shHIF-1a relative to MDA-
MB-231 cells at both the mRNA and protein levels. (c) Immunohistochemical staining for HIF-1a and DDX3 in sequential slices of a MDA-MB-231
tumor xenograft. Tumor sections were stained with antibodies that are specific for HIF-1a and DDX3. Samples were counterstained with hematoxylin
to reveal morphology. Error bars represent 6SD.
doi:10.1371/journal.pone.0017563.g006
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,1.5 to 2 fold but were not completely ablated, which is likely due
to promoter regulation by other transcription factors that are
active on these portions of the DDX3 promoter. Despite the
differences in the induction of luciferase activity qualitatively
similar data was obtained during CoCl2 treatment as compared to
untreated cells.
To support the sequence-specific binding by HIF-1 to HRE-1
during hypoxic conditions within the nucleus of live cells we
preformed ChIP assays. Overall, the mutated promoter-reporter
and ChIP assays indicate that HIF-1 binds to an HRE in the
proximal promoter of DDX3 under hypoxic conditions. Interest-
ingly the proximal hypoxic responsive element close to the
translation start site is highly conserved across eutherian mammals
(Figure 7). This conservation of promoter elements is an indication
that DDX3 expression in cells experiencing low O2 conditions is
an important trait and that a functional DDX3 under these
conditions is likely necessary during normal responses to hypoxia
but may be pathologic during breast cancer progression. Indicative
of this latter possibility is our observation that a portion of the
DDX3 protein expression pattern overlaps with that of HIF-1a
expression and that a similar lack of expression of both proteins is
seen in other areas of the immunohistochemical staining of
sequential tumor slices from a MDA-MB-231 xenograft model. In
addition, the expression levels of DDX3 transcript and protein
were reduced in HIF-1a knockdown MDA-MB-231 cell lines.
These findings indicate that DDX3 may have important
function(s) in the hypoxic environment of the tumor.
In summary, we have demonstrated, for the first time, that
hypoxia is an inducer of DDX3 mRNA and protein expression in
breast epithelial cell lines. Future studies aimed at the identifica-
tion of the target genes under DDX3 regulation should provide
important insights into a contributing molecular mechanism that
modulates protein expression profiles during hypoxia. This will
allow us to gain a better understanding of the protein repertoire
that is modulated by hypoxia during breast tumorigenesis.
Materials and Methods
Cell lines and culture conditions
MCF 10A, MCF 7 and MDA-MB-231 cells (ATCC, Manassas,
VA) were grown on standard tissue culture plastic ware in a 5%
CO2-humidified incubator at 37uC. For hypoxia MCF 10A and
MCF 7 cells were seeded at 1610
6 cells per 10 cm dish in
duplicate. Twenty-four hours later the plates were transferred to
modular incubators (Billups-Rothenberg Inc, USA) and flushed at
3 psi for 3 min with a mixture of 1% O2, 94% N2, and 5% CO2.A
modular chamber was used for each time point indicated in the
figures. All chambers were transferred for culture to a standard
37uC incubator along with normoxic duplicate plates. In other
experiments hypoxia mimetic conditions were chemically gener-
ated by treating cells with 200 mM cobalt chloride (CoCl2, Sigma,
St. Louis, Missouri) for the indicated times.
Quantitative real time PCR
Quantitative real time PCR was performed on RNA extracts
from MCF 10A and MCF 7 cells. Total RNA was prepared from
cultured cells under hypoxia (1% oxygen) for 0, 8, 12 and 24 h
RNA was isolated according to the manufacturer’s protocol
(Qiagen) and reverse transcribed using a cDNA synthesis kit
(Quanta BioSciences). The DDX3 mRNA sequence was amplified
by real time PCR using DDX3 sense: 59-GGAGGAAGTA-
CAGCCAGCAAAG-39 and antisense: 59-CTGCCAATGC-
CATCGTAATCACTC-39 primers. The relative expression of
DDX3 in each cell line was normalized to that of hypoxanthine
guanine phosphoribosyltransferase (HPRT) gene and gene ex-
pression in each sample was then compared with expression
during normoxic growth conditions.
RNA interference
To knock down HIF-1a expression in MCF 10A, MCF 7 and
MDA-MB-231 cells, a lentiviral expression vector (pRRL)
containing short hairpin (sh) RNA against HIF-1a mRNA was
used. A lentiviral vector carrying a shRNA against luciferase (luc-
shRNA) was used in the preparation of control virions.
Reporter assays
Cells were plated 24 h before transfection at 1610
5 cells per
well in a twenty four-well cell culture plate. Various DNA
constructs (250 ng) and 5 ng of Renilla construct (Promega) were
co-transfected using Trans IT-LTH (Mirus) transfection. For
hypoxia mimetic assays, transfected cells were maintained in
200 mM CoCl2 for an additional 12 h. Following incubation, cells
were lysed and luciferase activity was measured in a luminometer
(Berthhold Detection System, Oak Ridge, TN). All experiments
were performed in triplicate.
Plasmid constructions and site-directed mutagenesis
Promoter deletions have been described previously [51]. Specific
mutations were introduced into the luciferase reporter plasmids
using QuikChange site-directed mutagenesis kits from Stratagene.
Sequencesof sensemutagenesis primers were asfollows: HRE-1: 59-
GAGGGAGGGCACACGTTGTGGTACCTGACGTAGCCG-
GCTTTCC-39, HRE-2: 59-CGCACGCGACACCTACGGGG-
TACCGGCCTGCCGCCCTCTCAG-39, and HRE-3: 59-
GCGGAGGCGCGCGCGCGATATCCGGGGGGTTGGCC-
AGG-39 with mutated bases underlined. The generated plasmids
were designated M1, M2, M3, M1+2, M1+3, M2+3a n dM 1 +2+3
Figure 7. Comparison of regions of the DDX3 promoter among eutherian mammals. Conserved core hypoxia response elements (HRE-1, 2,
& 3), which are putative HIF-1 binding sites (indicated in bold and underlined) are shown. HRE-1 and surrounding sequences are highly conserved
across species.
doi:10.1371/journal.pone.0017563.g007
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sequencing.
Chromatin immunoprecipitation assay
ChIP was carried out following established protocols. Chroma-
tin complexes were immuno-precipitated using rabbit anti-HIF-1a
or anti-histone deacetylase (positive control) antibodies. Samples
prepared with anti-actin antibodies served as negative controls.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumor tissues from MDA-
MB-231 derived xenografts were used to study the expression
pattern of DDX3 and HIF-1a. Sections were deparaffinized in
xylene, blocked, and incubated with in-house generated polyclonal
rabbit anti-DDX3 antibody (1:5000) [16] and mouse or rabbit anti
HIF-1a antibody (1:1000, Novus Biologicals, CO, USA). Samples
were then rinsed and incubated with horseradish peroxidase
conjugated goat anti-rabbit whole IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) and stained with DAB (Sigma).
Sections were counterstained with hematoxylin Gill #3 (Sigma).
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